Sparks commentary - Oryzon Genomics

Healthcare

Sparks - Oryzon Genomics

More on this equity
testalize-me-0jE8ynV4mis-unsplash
Oryzon (BME: ORY) fortifies its IP portfolio
Published by Arron Aatkar, PhD

Oryzon Genomics has received an ‘Intention to grant’ communication from the European Patent Office relating to a patent application for its lead CNS asset, vafidemstat, entitled ‘Methods of treating borderline personality disorder’. Once granted, it will provide protection in Europe until at least 2040, excluding any potential patent term extensions that may provide additional protection. This news is incremental to Oryzon’s announcements earlier this quarter of the receipt of similar communications covering Australia, Malaysia, Mexico and Japan, fortifying the robust patent portfolio for the candidate.

Management is preparing for an end-of-Phase II meeting with the FDA to discuss a potential global registrational Phase III programme in borderline personality disorder; an update is expected in Q424.

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.